Statin Use in Prostate Cancer
An overview on statin use in prostate cancer. Read the article here.
Statin Use in Prostate Cancer Read More »
How 48 doctors think about active surveillance
A recent article exploring how physicians who manage prostate cancer regularly think about active surveillance and how to discuss this with their patients. Read the article here.
How 48 doctors think about active surveillance Read More »
When Facing Metastatic Prostate Cancer, Know What to Ask Your Doctor
Jan Manarite, executive vice president of Prostate Cancer International, discusses what a man with prostate cancer should do when his disease is progressing and his PSA levels are rising while on hormone therapy. Watch the video here.
When Facing Metastatic Prostate Cancer, Know What to Ask Your Doctor Read More »
Diet Intervention in Men on Active Surveillance for Prostate Cancer
A presentation of work assessing the feasibility of implementing a diet-based intervention in men with prostate cancer. Watch the interview here.
Diet Intervention in Men on Active Surveillance for Prostate Cancer Read More »
An Optimist’s Guide to Your Prostate
This is a comprehensive article from Esquire about most aspects of prostate cancer. Read the article.
An Optimist’s Guide to Your Prostate Read More »
Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer
A discussion of radiation techniques and genomic testing in prostate cancer. Read the article here.
Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer Read More »
Finasteride does not increase risk of prostate cancer death
The landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens’ risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study findings suggested there may be a link between use of the drug and a more lethal form of prostate cancer, but long-term follow-up shows that is not true. Read the article here.
Finasteride does not increase risk of prostate cancer death Read More »
Active surveillance in men with Gleason 3 + 4 = 7 prostate cancer at diagnosis
A critical question for men with favorable intermediate-risk prostate cancer (based primarily on a Gleason score of 3 + 4 = 7) can often be, “How safe would it be for me to go on active surveillance for a while after initial diagnosis?” Read the article here.
Active surveillance in men with Gleason 3 + 4 = 7 prostate cancer at diagnosis Read More »
Video: “How clinical trials have changed prostate cancer care”
March 2018 Awareness Night How clinical trials have changed prostate cancer care Dr. Andrew Loblaw BSc MD MSc FRCPC CIP Clinician Scientist , Ontario Association of Radiation OncologyStaff Radiation Oncologist & Clinician Scientist, Sunnybrook Health Sciences Centre Scientist, Sunnybrook Research Institute Fellow, American Society of Clinical Oncology (ASCO) Co-Chair, GU group for Cancer Care Ontario’s Program in Evidence-Based Care Previous Co-Chair, ASCO’s Genitourinary Advisory Group Professor, Department of Radiation Oncology at University of Toronto Professor,The Institute of Health Policy, Management and Evaluation (IHPME) CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 66:27 minutes
Video: “How clinical trials have changed prostate cancer care” Read More »
When can active surveillance be less active?
A substantial proportion of men with low-risk prostate cancer can safely be followed with a de-intensified active surveillance protocol. Read the article here.
When can active surveillance be less active? Read More »